Effects of clozapine and 2,5-dimethoxy-4-methylamphetamine [DOM] on 5-HT2A receptor expression in discrete brain areas.

M M Doat-Meyerhoefer, R Hard, J C Winter, R A Rabin
Author Information
  1. M M Doat-Meyerhoefer: Department of Pharmacology and Toxicology, 102 Farber Hall, School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14214, USA.

Abstract

Activation of 5-HT2A receptors has been shown to be an essential component of the discriminative stimulus effects of indoleamine and phenethylamine hallucinogens. The objective of the present study was to determine the neuroanatomical location of the 5HT2A receptors which may be responsible for the stimulus effects of the phenethylamine hallucinogen [-]2,5-dimethoxy-4-methylamphetamine (DOM). It was hypothesized that brain areas containing altered 5-HT2A receptor expression in the context of a similar alteration in DOM-induced stimulus control might be important in mediating the stimulus effects of DOM. Fisher 344 rats were treated with either clozapine (25 mg/kg/day) or DOM (2 mg/kg/day) for 7 days, and the consequences of these drug treatment regimens on DOM-induced stimulus control and on 5-HT2A receptor expression in several brain areas were determined. Chronic administration of clozapine was associated with a wide-spread decrease in levels of 5-HT2A/2C receptors. Conversely, treatment with DOM had varied effects including a neuroanatomically selective decrease in 5-HT2A/2C receptor levels that was restricted to the olfactory nucleus. Both chronic treatment with DOM and clozapine decreased the stimulus effects of DOM. The present findings suggest a role for the olfactory nucleus in producing the stimulus effects of DOM.

References

  1. Psychopharmacology (Berl). 1995 Oct;121(3):364-72 [PMID: 8584619]
  2. Psychopharmacology (Berl). 1995 Oct;121(3):347-56 [PMID: 8584617]
  3. Neuroscience. 1996 Jul;73(2):531-40 [PMID: 8783268]
  4. Naunyn Schmiedebergs Arch Pharmacol. 1997 Oct;356(4):446-54 [PMID: 9349630]
  5. Brain Res Mol Brain Res. 1997 Aug;48(1):45-52 [PMID: 9379848]
  6. Brain Res. 1997 Nov 14;775(1-2):225-8 [PMID: 9439849]
  7. Trends Pharmacol Sci. 1997 Dec;18(12):456-64 [PMID: 9458693]
  8. Neuroreport. 1998 Dec 1;9(17):3897-902 [PMID: 9875725]
  9. J Neurochem. 1999 Apr;72(4):1593-9 [PMID: 10098866]
  10. Psychopharmacology (Berl). 1999 Jun;144(3):248-54 [PMID: 10435391]
  11. Neuropsychopharmacology. 1999 Sep;21(3):325-40 [PMID: 10457530]
  12. Biochem Pharmacol. 1999 Oct 1;58(7):1081-8 [PMID: 10484065]
  13. Pharmacol Biochem Behav. 1999 Oct;64(2):283-93 [PMID: 10515304]
  14. Psychopharmacology (Berl). 2005 May;179(2):393-401 [PMID: 15565434]
  15. Am J Psychiatry. 2000 May;157(5):828-30 [PMID: 10784482]
  16. Eur J Pharmacol. 2000 May 19;396(2-3):67-75 [PMID: 10822058]
  17. Mol Pharmacol. 2001 Oct;60(4):690-9 [PMID: 11562430]
  18. Eur J Pharmacol. 2001 Aug 3;425(1):21-32 [PMID: 11672571]
  19. Brain Res Bull. 2001 Nov 15;56(5):441-51 [PMID: 11750789]
  20. Brain Res Bull. 2001 Nov 15;56(5):495-507 [PMID: 11750795]
  21. Int J Neuropsychopharmacol. 2002 Jun;5(2):153-8 [PMID: 12135540]
  22. Am J Psychiatry. 2002 Sep;159(9):1593-5 [PMID: 12202283]
  23. J Clin Psychopharmacol. 2002 Dec;22(6):622-4 [PMID: 12454564]
  24. J Neurochem. 2003 Apr;85(1):1-13 [PMID: 12641722]
  25. Life Sci. 2003 Apr 18;72(22):2429-49 [PMID: 12650852]
  26. Arch Gen Psychiatry. 2003 Jun;60(6):578-84 [PMID: 12796221]
  27. Naunyn Schmiedebergs Arch Pharmacol. 2003 Aug;368(2):79-90 [PMID: 12861437]
  28. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72 [PMID: 14642974]
  29. Psychopharmacology (Berl). 2004 Jun;174(1):17-24 [PMID: 15205874]
  30. Pharmacol Biochem Behav. 2004 Sep;79(1):25-30 [PMID: 15388280]
  31. J Pharmacol Exp Ther. 1982 May;221(2):303-8 [PMID: 7077527]
  32. Psychiatry Res. 1984 Aug;12(4):277-85 [PMID: 6239298]
  33. Life Sci. 1984 Dec 17;35(25):2505-11 [PMID: 6513725]
  34. Life Sci. 1985 Feb 25;36(8):713-21 [PMID: 2983168]
  35. Brain Res. 1985 Nov 4;346(2):231-49 [PMID: 4052777]
  36. Psychopharmacology (Berl). 1986;88(4):434-44 [PMID: 3010361]
  37. Psychopharmacology (Berl). 1988;94(2):213-6 [PMID: 3127847]
  38. Brain Res. 1989 May 22;487(2):288-98 [PMID: 2525063]
  39. Eur J Pharmacol. 1989 Apr 12;163(1):145-9 [PMID: 2545460]
  40. Psychopharmacology (Berl). 1989;98(4):495-9 [PMID: 2505289]
  41. Life Sci. 1989;45(15):1397-406 [PMID: 2571912]
  42. Neuropsychopharmacology. 1990 Apr;3(2):137-48 [PMID: 1969270]
  43. Mol Pharmacol. 1990 Nov;38(5):594-8 [PMID: 2233696]
  44. Mol Pharmacol. 1990 Nov;38(5):604-9 [PMID: 2233697]
  45. J Pharmacol Exp Ther. 1990 Nov;255(2):843-57 [PMID: 2243353]
  46. J Pharmacol Exp Ther. 1992 Aug;262(2):692-8 [PMID: 1501117]
  47. Schizophr Res. 1993 Jan;8(3):245-50 [PMID: 8094630]
  48. Mol Pharmacol. 1993 Mar;43(3):349-55 [PMID: 8383800]
  49. Neuropsychopharmacology. 1993 Sep;9(2):117-24 [PMID: 8216694]
  50. Synapse. 1993 Aug;14(4):324-31 [PMID: 8248854]
  51. J Neurochem. 1994 Oct;63(4):1255-60 [PMID: 7931277]
  52. Toxicol Pathol. 1994 May-Jun;22(3):300-15 [PMID: 7817120]
  53. Eur J Pharmacol. 1994 Oct 13;264(1):99-102 [PMID: 7530204]
  54. J Pharmacol Exp Ther. 1995 Nov;275(2):674-80 [PMID: 7473154]
  55. J Pharmacol Exp Ther. 1995 Dec;275(3):1638-46 [PMID: 8531139]
  56. Neuropsychopharmacology. 1995 Oct;13(2):139-50 [PMID: 8597525]

Grants

  1. R01 DA003385-16/NIDA NIH HHS
  2. F31 MH012696/NIMH NIH HHS
  3. MH12696/NIMH NIH HHS
  4. R01 DA003385/NIDA NIH HHS
  5. R56 DA003385/NIDA NIH HHS
  6. DA 03385/NIDA NIH HHS

MeSH Term

DOM 2,5-Dimethoxy-4-Methylamphetamine
Amphetamines
Animals
Binding, Competitive
Brain
Clozapine
Discrimination, Psychological
Hallucinogens
Iodine Radioisotopes
Male
Rats
Rats, Inbred F344
Receptor, Serotonin, 5-HT2A
Serotonin 5-HT2 Receptor Agonists
Serotonin 5-HT2 Receptor Antagonists
Serotonin Antagonists
Serotonin Receptor Agonists

Chemicals

Amphetamines
Hallucinogens
Iodine Radioisotopes
Receptor, Serotonin, 5-HT2A
Serotonin 5-HT2 Receptor Agonists
Serotonin 5-HT2 Receptor Antagonists
Serotonin Antagonists
Serotonin Receptor Agonists
DOM 2,5-Dimethoxy-4-Methylamphetamine
Clozapine
4-iodo-2,5-dimethoxyphenylisopropylamine

Word Cloud

Created with Highcharts 10.0.0stimulusDOMeffects5-HT2Areceptorclozapinereceptorsbrainareasexpressiontreatmentphenethylaminepresent5-dimethoxy-4-methylamphetamineDOM-inducedcontrolmg/kg/day2decreaselevels5-HT2A/2ColfactorynucleusActivationshownessentialcomponentdiscriminativeindoleaminehallucinogensobjectivestudydetermineneuroanatomicallocation5HT2Amayresponsiblehallucinogen[-]2hypothesizedcontainingalteredcontextsimilaralterationmightimportantmediatingFisher344ratstreatedeither257daysconsequencesdrugregimensseveraldeterminedChronicadministrationassociatedwide-spreadConverselyvariedincludingneuroanatomicallyselectiverestrictedchronicdecreasedfindingssuggestroleproducingEffects[DOM]discrete

Similar Articles

Cited By